{"filing":{"accession_number":"0001140361-26-033282","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-13","primary_document":"ef20080234_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126033282/ef20080234_8k.htm"},"events":[{"id":28161,"run_id":25746,"accession_number":"0001140361-26-033282","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Existing shareholder KKR Genetic Disorder L.P. entered into an Underwriting Agreement for a secondary offering of 5,000,000 shares of common stock at $78.00 per share, with the Company not receiving proceeds but existing shareholders experiencing dilution of ownership percentages.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29994,"accession_number":"0001140361-26-033282","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This Item 1.01 discloses entry into an Underwriting Agreement for a secondary offering of 5,000,000 shares of common stock by existing shareholder KKR Genetic Disorder L.P. at $78.00 per share. While the Company itself does not receive proceeds, the secondary offering represents a material dilutive event to existing shareholders' ownership percentages. The transaction is substantial in size and scope, involving major underwriters (William Blair, Goldman Sachs, KKR Capital Markets) and an effective shelf registration statement. However, the classification as \"dilutive_issuance\" is somewhat attenuated here because this is a secondary offering by an existing shareholder rather than a primary issuance by the Company itself to raise capital—the Company receives no proceeds. This could alternatively be viewed as a shareholder liquidity event with limited direct financial impact to the Company, though it remains material to investor assessment of ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T13:07:14.770706+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29995,"accession_number":"0001140361-26-033282","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.75,"reasoning":"This disclosure announces a secondary offering of 5,000,000 shares by an existing shareholder (KKR Genetic Disorder L.P.), not by BridgeBio itself. The Company explicitly states it \"is not selling any shares and will not receive any of the proceeds of the offering.\" While secondary offerings involve equity securities, this is a shareholder liquidity event rather than a dilutive issuance by the company, and does not materially affect BridgeBio's capital structure or financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T13:07:14.770706+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29994,"accession_number":"0001140361-26-033282","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This Item 1.01 discloses entry into an Underwriting Agreement for a secondary offering of 5,000,000 shares of common stock by existing shareholder KKR Genetic Disorder L.P. at $78.00 per share. While the Company itself does not receive proceeds, the secondary offering represents a material dilutive event to existing shareholders' ownership percentages. The transaction is substantial in size and scope, involving major underwriters (William Blair, Goldman Sachs, KKR Capital Markets) and an effective shelf registration statement. However, the classification as \"dilutive_issuance\" is somewhat attenuated here because this is a secondary offering by an existing shareholder rather than a primary issuance by the Company itself to raise capital—the Company receives no proceeds. This could alternatively be viewed as a shareholder liquidity event with limited direct financial impact to the Company, though it remains material to investor assessment of ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T13:07:14.770706+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-17"},{"id":29995,"accession_number":"0001140361-26-033282","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.75,"reasoning":"This disclosure announces a secondary offering of 5,000,000 shares by an existing shareholder (KKR Genetic Disorder L.P.), not by BridgeBio itself. The Company explicitly states it \"is not selling any shares and will not receive any of the proceeds of the offering.\" While secondary offerings involve equity securities, this is a shareholder liquidity event rather than a dilutive issuance by the company, and does not materially affect BridgeBio's capital structure or financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T13:07:14.770706+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-08-17"}]}